PharmaFocus Today – Page 263 – media

Taysha Drops Gene Therapy Candidate as FDA Again Calls for Study Changes

By Connor Lynch Pictured: FDA sign in its headquarters/iStock, Grandbrothers Taysha Gene Therapies has decided to drop its lead experimental AAV-based gene therapy candidate after the FDA reiterated calls for the company to put the treatment through a randomized, double-blind placebo-controlled trial. The Dallas-based company announced on Tuesday that it would no longer be developing its TSHA-120 treatment for giant axonal neuropathy (GAN) based on the FDA’s Type C meeting feedback regarding the therapy’s potential pathway. “FDA continues to recommend a randomized, double-blind, placebo-controlled trial as the optimal path to demonstrate efficacy in TSHA-120,” the company said in a statement. Taysha noted in the announcement that the FDA “provided a potential path for a single-arm trial with an external control group matched with to-be treated patients by multiple prognostic factors and recommended longer term follow up to account for potential bias.” CEO Sean Nolan said in a statement that the ...
- Source: drugdu
- 187
- September 22, 2023
J&J starts trial of pulsed field ablation catheter with mapping feedback

Dive Brief Johnson & Johnson has begun a clinical trial of another investigational pulsed field ablation (PFA) device, opening a new front in its pursuit of a potentially significant cardiovascular opportunity. The treatment of the first patients with the Omnypulse catheter comes months after J&J posted data on Varipulse, another PFA device to treat atrial fibrillation. J&J also has a PFA and radiofrequency dual energy device in late-phase development. Omnypulse expands J&J’s portfolio of investigational devices with a catheter that gathers contact force data to support mapping. Analysts have identified the combination of PFA and mapping, which J&J sees as a key feature of its systems, as a threat to Abbott’s electrophysiology unit. Dive Insight It has been only three weeks since Boston Scientific notched a milestone in the race for the first-generation PFA market with positive clinical trial results. Boston Scientific and Medtronic are leading the way. Stifel analysts ...
- Source: drugdu
- 614
- September 21, 2023
New NIH plan outlines HSV research framework with four strategic priorities

In response to the persistent health challenges of herpes simplex virus 1 (HSV-1) and HSV-2, today the National Institutes of Health released the Strategic Plan for Herpes Simplex Virus Research. An NIH-wide HSV Working Group developed the plan, informed by feedback from more than 100 representatives of the research and advocacy communities and interested public stakeholders. The plan outlines an HSV research framework with four strategic priorities: improving fundamental knowledge of HSV biology, pathogenesis, and epidemiology; accelerating research to improve HSV diagnosis; improving strategies to treat HSV while seeking a curative therapeutic; and, advancing research to prevent HSV infection. HSV-1 and HSV-2 are among the most common viral infections in the United States. HSV can cause recurring blisters or sores. In severe cases HSV may lead to life-threatening or long-term complications, typically in the central nervous system. There are no licensed preventive HSV vaccines, and there is no cure. Up ...
- Source: drugdu
- 234
- September 21, 2023
Tribunal upholds £130M fine after UK authorities probed 10,000% price hike

Auden Mckenzie and Actavis UK—now known as Accord-UK—will remain on the hook to pay hefty fines for their roles in introducing costly price hikes on hydrocortisone tablets.In a judgment published Monday, the U.K.’s Competition Appeal Tribunal (CAT) upheld previous findings by the country’s Competition and Markets Authority (CMA) that multiple drugmakers had charged “excessive and unfair prices” for generic hydrocortisone over the course of 10 years. Hydrocortisone tablets treat adrenal insufficiency, including serious conditions such as Addison’s disease. In the U.K., the medicine is funded by England’s National Health Service. The tribunal’s decision comes a little more than two years after CMA doled out fines worth more than 260 million pounds sterling ($360 million) to more than 10 pharmaceutical companies. The punishment followed a long-running investigation by the U.K. into the steep cost of hydrocortisone. From 2008 to 2016, the med’s price grew by 10,000%, costing taxpayers hundreds of millions ...
- Source: drugdu
- 170
- September 21, 2023
Kinnate Biopharma announces 70% layoffs and pipeline restructuring

Kinnate Biopharma plans to sack around 70% of its workforce and stop the development of three programmes as a result of its strategic review. The company expects to retain 28 full-time employees after the layoffs are concluded, per the 18 September press release. The US-based oncology company has also decided to consider strategic alternatives for the exarafenib monotherapy programme and the asset KIN-3248, which is designed for use in cancers with FGFR2 and FGFR3 alterations. Despite the clearing of KIN-7136’s investigational new drug application (IND), Kinnate will also not be going ahead with its Phase I trial. The strategic review reflects multiple factors that include its cash runway and the commercial potential of its programmes, based on the 18 September update. Although exarafenib was well tolerated by patients in a Phase I trial (NCT04913285), it displayed limited anti-tumour activity in subjects with Class II alterations. The company has decided to ...
- Source: drugdu
- 106
- September 21, 2023
BeiGene and Nona Biosciences expand collaboration for antibody discovery

BeiGene will utilise Nona’s Harbour Mice platform as part of the agreement BeiGene and Nona Biosciences have announced an agreement to expand their strategic collaboration for antibody discovery. The collaboration will allow BeiGene to utilise Nona’s Harbour Mice platform – a fully human transgenic mouse platform – to further improve therapeutic antibody discovery efficiency and flexibility. BeiGene first obtained the rights to use the proprietary Harbour Mice H2L2 platform for multiple antibody programmes in 2018 as part of the now expanded collaboration. Harbour Mice works to generate fully human monoclonal antibodies in classical two light and two heavy chain (H2L) formats and heavy chain only (HCAb) formats. The H2L platform allows mice to bear fully human immunoglobulin genes with robust B cell development and antibody maturation. The HCAb platform is the world’s first human HCAb transgenic mouse platform that works to generate fully human heavy chain-only antibodies. It allows the ...
- Source: drugdu
- 204
- September 21, 2023
CSL Seqirus highlights impact of flu vaccines on reducing strain on healthcare resources

CSL Seqirus has unveiled new data highlighting the potential impact of influenza vaccines on reducing the burden seasonal flu has on hospitals and broader healthcare systems. The analyses were presented at this year’s European Scientific Working Group on Influenza (ESWI) Conference. Seasonal flu is an acute respiratory infection caused by influenza viruses, which circulate in all parts of the world. Although most people can recover within a week without requiring medical attention, the flu can cause severe illness among high-risk groups such as young children, older adults, pregnant individuals and those with serious medical conditions. In France, approximately 2 to 6 million people are affected by influenza every year, leading to over 20,000 hospitalisations and 10,000 excess deaths, 90% of which occur in older adults. According to findings from a dynamic transmission model, standard-dose quadrivalent flu vaccines for older adults could reduce hospitalisations by 11.1% to 30.0% and cut ICU ...
- Source: drugdu
- 113
- September 21, 2023
Sanofi Sells 11 CNS Assets to Pharmanovia including Frisium and Gardenal

By Tristan Manalac Pictured: Sanofi’s Germany office at night/iStock, Panama7 Sanofi on Monday offloaded 11 brands in its central nervous system portfolio to U.K-based company Pharmanovia, including epilepsy drugs Frisium and Gardenal. The companies did not disclose specific terms of the agreement, but revealed that the medicines span four therapeutic areas—all with ongoing unmet need: psycholeptics, anxiolytics, anti-epileptics and anti-psychotics. Though not all these drugs are approved in every market, they still have “clear synergy” with Pharmanovia’s existing portfolio and will fit well with the company’s “core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need,” CEO James Burt said in a statement. Among the divested drugs are several brands of the benzodiazepine clobazam, including Sentil, Urbanol, Noiafren, Castilium and Frisium. All of these are for the treatment of anxiety in certain patient subgroups; Frisium can also be used as an adjunctive treatment in ...
- Source: drugdu
- 187
- September 21, 2023
Novartis Returns Cancer Asset Tislelizumab to BeiGene

By Tristan Manalac Pictured: Novartis’ head office in Canada/iStock, JHVEPhoto Novartis on Tuesday gave back the investigational monoclonal antibody tislelizumab to BeiGene, returning worldwide rights to develop, manufacture and commercialize the anti-PD-1 candidate to the cancer-focused biotech. Also on Tuesday, BeiGene announced that the European Commission had approved tislelizumab for patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who had previously failed platinum-based chemotherapy. The treatment will be marketed under the brand name Tevimbra. After more than a year of regulatory delay, the FDA has also accepted BeiGene’s Biologics License Application (BLA) for tislelizumab as a first-line treatment option in this indication, according to Tuesday’s announcement. Novartis and BeiGene first entered into a collaboration and license agreement over tislelizumab in January 2021 to develop tislelizumab in ESCC, as well as other malignant diseases such as non-small cell lung cancer and hepatocellular carcinoma. In July 2022, however, ...
- Source: drugdu
- 115
- September 21, 2023
FDA finalizes breakthrough device changes to target health inequities

Dive Brief The Food and Drug Administration has finalized changes to its breakthrough devices guidance, adopting revisions that could accelerate development of products that address health inequities. Eleven months ago, the FDA proposed updating its breakthrough guidance to clarify that devices that improve accessibility, and thereby tackle health inequities, can qualify for the program. The proposals received broadly positive feedback, including from industry trade group AdvaMed, leading the FDA to finalize the changes with only minor revisions and schedule a webinar to discuss its new policy. Dive Insight The FDA designed the breakthrough program to support development of devices that could better treat or diagnose life-threatening or irreversibly debilitating diseases or conditions. Originally, the guidance lacked a specific reference to accessibility as a way that devices can improve care. In October, the FDA proposed updating the guidance to explain that it considers the “totality of information regarding the proposed device, ...
- Source: drugdu
- 210
- September 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.